Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

Low income and high social deprivation are independently associated with adverse clinical outcomes in patients with HCM.

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

In veterans with type 2 diabetes, treatment with GLP-1 receptor agonists was associated with a reduced risk for various substance use disorders compared with sodium-glucose cotransporter-2, or SGLT-2, ...

Industry leaders discuss how technology adoption, integrated data systems, and operational readiness are shaping ...

Japan has approved two stem cell-based therapies for treating Parkinson's disease and heart failure in a world first, through ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.

The digital transformation of healthcare is accelerating, but not fast enough. Like the financial sector in the early 2000s, healthcare is under pressure to modernize. Patients expect medical record ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus” or the 'Company”), a healthcare company developing and commercializing ...

Q4 2025 Management View CEO David Chang described 2026 as a “defining year” focused on “delivering meaningful clinical milestones with rigor and speed.” He emphasized that Allogene’s approach is to ...